BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 19006661)

  • 21. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.
    Ott K; Sendler A; Becker K; Dittler HJ; Helmberger H; Busch R; Kollmannsberger C; Siewert JR; Fink U
    Gastric Cancer; 2003; 6(3):159-67. PubMed ID: 14520529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
    Sudarshan M; Alcindor T; Ades S; Aloraini A; van Huyse M; Asselah J; David M; Frechette D; Brisson S; Thirlwell M; Ferri L
    Ann Surg Oncol; 2015 Jan; 22(1):324-30. PubMed ID: 25023544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Neoadjuvant chemotherapy for locally advanced gastric cancer].
    Kalmár K; Cseke L; Káposztás Z; Horváth G; Varga E
    Magy Seb; 2003 Oct; 56(5):177-84. PubMed ID: 15022621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma.
    Weese JL; Harbison SP; Stiller GD; Henry DH; Fisher SA
    Surgery; 2000 Oct; 128(4):564-71. PubMed ID: 11015089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy in advanced gastric cancer--results of a pilot study.
    Shukla NK; Deo SV; Asthana S; Raina V; Dronamaraju SS
    Trop Gastroenterol; 2002; 23(2):94-6. PubMed ID: 12632980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
    Di Bartolomeo M; Buzzoni R; Mariani L; Ferrario E; Katia D; Gevorgyan A; Zilembo N; Bordonaro R; Bochicchio AM; Massidda B; Ardizzoia A; Marini G; Aitini E; Schieppati G; Comella G; Pinotti G; Palazzo S; Cicero G; Bajetta E; ; Villa E; Fagnani D; Reguzzoni G; Agostana B; Oliani C; Kildani B; Duro M; Botta M; Mozzana R; Mantovani G
    Oncology; 2006; 71(5-6):341-6. PubMed ID: 17855795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
    Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
    Eur J Surg Oncol; 2007 Sep; 33(7):843-8. PubMed ID: 17207959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer.
    Yano M; Shiozaki H; Inoue M; Tamura S; Doki Y; Yasuda T; Fujiwara Y; Tsujinaka T; Monden M
    World J Surg; 2002 Sep; 26(9):1155-9. PubMed ID: 12209246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.
    Fazio N; Biffi R; Maibach R; Hayoz S; Thierstein S; Brauchli P; Bernhard J; Stupp R; Andreoni B; Renne G; Crosta C; Morant R; Chiappa A; Luca F; Zampino MG; Huber O; Goldhirsch A; de Braud F; Roth AD; ;
    Ann Oncol; 2016 Apr; 27(4):668-73. PubMed ID: 26712905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.
    Brenner B; Shah MA; Karpeh MS; Gonen M; Brennan MF; Coit DG; Klimstra DS; Tang LH; Kelsen DP
    Ann Oncol; 2006 Sep; 17(9):1404-11. PubMed ID: 16788003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer?
    Mansour JC; Tang L; Shah M; Bentrem D; Klimstra DS; Gonen M; Kelsen DP; Brennan MF; Coit DG
    Ann Surg Oncol; 2007 Dec; 14(12):3412-8. PubMed ID: 17909917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of neoadjuvant chemotherapy with paclitaxel, 5-fluorouracil and cisplatin for advanced gastric cancer with pyloric stenosis].
    Yamaguchi K; Nakagawa S; Yabusaki H; Nashimoto A
    Gan To Kagaku Ryoho; 2007 Dec; 34(13):2241-4. PubMed ID: 18079622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
    Inal A; Kaplan MA; Kucukoner M; Isikdogan A
    Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Neoadjuvant chemotherapy in high-grade advanced gastric cancer with protracted infusional 5-fluorouracil and consecutive low-dose cisplatin].
    Kondo K; Murase M; Yokoyama Y; Kato J; Hibi K; Kasai Y; Akiyama S; Ito K; Takagi H
    Gan To Kagaku Ryoho; 1996 Sep; 23(10):1299-303. PubMed ID: 8831742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma.
    Alexander HR; Grem JL; Hamilton JM; Pass HI; Hong M; Fraker DL; Steinberg SM; McAtee N; Allegra BC; Johnston PG
    Cancer J Sci Am; 1995; 1(1):49-54. PubMed ID: 9166454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients.
    Saito M; Kiyozaki H; Takata O; Suzuki K; Rikiyama T
    World J Surg Oncol; 2014 Dec; 12():406. PubMed ID: 25551581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer.
    Kos FT; Uncu D; Ozdemir N; Budakoglu B; Odabaş H; Abali H; Oksuzoglu B; Aksoy S; Zengin N
    Chemotherapy; 2011; 57(3):230-5. PubMed ID: 21597287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer.
    Kinoshita J; Fushida S; Tsukada T; Oyama K; Okamoto K; Makino I; Nakamura K; Miyashita T; Tajima H; Takamura H; Ninomiya I; Ohta T
    Eur J Surg Oncol; 2015 Oct; 41(10):1354-60. PubMed ID: 26028256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Neoadjuvant chemotherapy in advanced stomach cancer--a case of complete response].
    Káposztás Z; Cseke L; Kalmár K; Horváth OP
    Magy Seb; 2002 Oct; 55(5):321-4. PubMed ID: 12474518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.